SIHUAN PHARM (00460) has appointed Che Yu Xuan as a non-executive director, and the dual-driven strategy has resulted in a doubling of mid-term profits.

SIHUAN PHARM (00460) recently underwent an optimization upgrade of its governance structure and announced the appointment of Mr. Che Yuxuan as a non-executive director and a member of the board's risk management committee, effective from August 26, 2026. With his international research background and diverse perspective, the addition of the new non-executive director is expected to inject new momentum into the company's commercialization of innovative drug pipelines and AI research and development. The announcement indicates that Mr. Che Yuxuan holds a Bachelor's degree in Biology from the University of Washington. He has previously served as a data science researcher at Massachusetts General Hospital and worked in marketing and sales at Sanofi Pasteur. Notably, Mr. Che has long been deeply involved in the biopharmaceutical field, possessing a compound background that includes frontline research, commercialization with multinational pharmaceutical companies, and strategic management in innovative pharmaceutical enterprises. He has a deep understanding of the development, clinical advancement, and commercialization of innovative drugs, accumulating rich experience in the industry. Market analysis suggests that his professional foundation in the biopharmaceutical sector aligns closely with SIHUAN PHARM's current dual-driven strategy of "medical aesthetics + innovative drugs." His entry into the board is expected to strengthen the companys strategic decision-making and resource integration capabilities within its innovative drug sector, positively impacting the company's long-term development. Regarding performance, SIHUAN PHARM recently released its mid-year results for 2026, reporting total revenue of 1.161 billion yuan, a year-on-year increase of 1.3%. The profit attributable to the companys owners was 225 million yuan, up 119% year-on-year. The revenue growth was primarily driven by the medical aesthetics and innovative drug businesses, with medical aesthetics revenue reaching approximately 693 million yuan, an increase of about 18.5% year-on-year. The steady growth of the core product, LetibotulinumtoxinA (botulinum toxin), along with the ongoing expansion of regenerative medical aesthetic products (including youthful injections) and functional medical aesthetic products, helped maintain growth in the related medical aesthetics business. Revenue from innovative drugs and other pharmaceuticals was approximately 261 million yuan, an increase of about 349.1% year-on-year. The commercialization process of the innovative drug business continues to advance. The commercialization and internationalization progress of multiple approved products are proceeding well, leading to significant growth in combined revenue. Compared to the previous net loss, there was a slight increase in net profit this period.